{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:02:01Z","timestamp":1784822521460,"version":"3.55.0"},"reference-count":0,"publisher":"HMP Communications, LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wounds"],"abstract":"<jats:p>Background. Diabetic foot ulcers (DFUs) are a significant complication of diabetes, leading to high morbidity rate, amputation, and health care costs. Autologous blood-derived products, including autologous whole blood clot (AWBC), platelet-rich plasma, and platelet-rich fibrin, have emerged as promising treatments that leverage the body\u2019s own healing mechanisms. Objective. To evaluate the efficacy of autologous blood-derived products compared with standard-of-care (SOC) treatment in achieving complete healing of DFUs by 12 weeks. Methods. A systematic review and meta-analysis of sources published through April 2025 was performed following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. PubMed, Embase, and the Cochrane Library were searched. Randomized controlled trials (RCTs) reporting complete healing at 12 weeks were included. Data were pooled using a random effects model to calculate odds ratio (OR) with 95% CI. Results. Six RCTs with a total of 629 patients met the inclusion criteria. Autologous blood-derived products significantly improved the odds of complete healing at 12 weeks compared with SOC (pooled OR, 2.24; 95% CI, 1.47-3.41; P = .0045). Among these products, AWBC demonstrated the highest efficacy, and there was minimal indication of publication bias. Conclusion. Autologous blood-derived products significantly improve healing outcomes in DFUs compared with SOC, supporting their clinical use. Further research should refine product preparation methods and treatment durations to maximize efficacy.<\/jats:p>","DOI":"10.25270\/wnds\/25085","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:06:31Z","timestamp":1784819191000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Autologous Blood-Derived Therapies in Diabetic Foot Ulcers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.25270","volume":"38","author":[{"given":"Robert J.","family":"Snyder","sequence":"first","affiliation":[{"name":"Centre for Medical Education, Cardiff University School of Medicine, Cardiff, Wales, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lee","sequence":"additional","affiliation":[{"name":"UCLA Fielding School of Public Health, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10906","published-online":{"date-parts":[[2026,7]]},"container-title":["Wounds: a compendium of clinical research and practice"],"original-title":[],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:06:31Z","timestamp":1784819191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hmpgloballearningnetwork.com\/site\/wounds\/systematic-review\/efficacy-autologous-blood-derived-therapies-diabetic-foot-ulcers"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":0,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.25270\/wnds\/25085","relation":{},"ISSN":["1943-2704"],"issn-type":[{"value":"1943-2704","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}